Literature DB >> 21727913

Bone: osteoporosis therapy--time to consider renal function.

Jorge B Cannata-Andía1, Carlos Gómez-Alonso.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21727913     DOI： 10.1038/nrendo.2011.114

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  8 in total

1.  Effects of denosumab on fracture and bone mineral density by level of kidney function.

Authors:  Sophie A Jamal; Osten Ljunggren; Catherine Stehman-Breen; Steven Ron Cummings; Michael R McClung; Stefan Goemaere; Peter R Ebeling; Edward Franek; Yu-Ching Yang; Ogo I Egbuna; Steven Boonen; Paul D Miller
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

2.  Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.

Authors:  Paul D Miller; Christian Roux; Steven Boonen; Ian P Barton; Lisa E Dunlap; David E Burgio
Journal:  J Bone Miner Res       Date:  2005-08-22       Impact factor: 6.741

3.  Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.

Authors:  P D Miller; E N Schwartz; P Chen; D A Misurski; J H Krege
Journal:  Osteoporos Int       Date:  2006-09-30       Impact factor: 4.507

4.  Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.

Authors:  Sophie A Jamal; Douglas C Bauer; Kristine E Ensrud; Jane A Cauley; Marc Hochberg; Areef Ishani; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2007-04       Impact factor: 6.741

5.  Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.

Authors:  A Levin; G L Bakris; M Molitch; M Smulders; J Tian; L A Williams; D L Andress
Journal:  Kidney Int       Date:  2006-11-08       Impact factor: 10.612

6.  Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxyvitamin D cut-off levels.

Authors:  Carlos Gómez-Alonso; Manuel L Naves-Díaz; Jose L Fernández-Martín; Jose B Díaz-López; Maria T Fernández-Coto; Jorge B Cannata-Andía
Journal:  Kidney Int Suppl       Date:  2003-06       Impact factor: 10.545

7.  The effect of raloxifene treatment in postmenopausal women with CKD.

Authors:  Areef Ishani; Terri Blackwell; Sophie A Jamal; Steven R Cummings; Kristine E Ensrud
Journal:  J Am Soc Nephrol       Date:  2008-04-09       Impact factor: 10.121

8.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors: 
Journal:  Kidney Int Suppl       Date:  2009-08       Impact factor: 10.545
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.